Entrada Therapeutics Inc (TRDA)
14.10
-0.67
(-4.54%)
USD |
NASDAQ |
Jun 26, 16:00
15.00
+0.90
(+6.38%)
After-Hours: 20:00
Entrada Therapeutics Cash and Short Term Investments (Quarterly): 327.41M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 327.41M |
| December 31, 2023 | 351.97M |
| September 30, 2023 | 353.58M |
| June 30, 2023 | 376.79M |
| March 31, 2023 | 411.63M |
| December 31, 2022 | 188.71M |
| September 30, 2022 | 215.57M |
| Date | Value |
|---|---|
| June 30, 2022 | 244.25M |
| March 31, 2022 | 263.90M |
| December 31, 2021 | 291.06M |
| September 30, 2021 | 122.17M |
| June 30, 2021 | 136.95M |
| December 31, 2020 | 39.04M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
39.04M
Minimum
Dec 2020
411.63M
Maximum
Mar 2023
255.62M
Average
263.90M
Median
Mar 2022
Cash and Short Term Investments (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 310.41M |
| Vertex Pharmaceuticals Inc | 10.17B |
| Sarepta Therapeutics Inc | 1.391B |
| PTC Therapeutics Inc | 884.81M |
| GlycoMimetics Inc | 31.28M |